Arcus Biosciences (NYSE: RCUS) net income
Arcus Biosciences reported a net loss of $353.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $283.0m. Earnings per share were −$3.29.
Arcus Biosciences's best year of the last 9 was fiscal 2021. It reported a loss in 8 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$353.0m | — | −142.9% | −$3.29 |
| 2024 | −$283.0m | — | −109.7% | −$3.14 |
| 2023 | −$307.0m | — | −262.4% | −$4.15 |
| 2022 | −$267.0m | −603.8% | −238.4% | −$3.71 |
| 2021 | $53.0m | — | 13.8% | $0.76 |
| 2020 | −$123.0m | — | −157.7% | −$2.24 |
| 2019 | −$84.7m | — | −564.7% | −$1.93 |
| 2018 | −$49.6m | — | −593.7% | — |
| 2017 | −$53.1m | — | −3,756.7% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arcus Biosciences net income compared with its sector
By net income for its latest fiscal year, Arcus Biosciences ranks 457th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Arcus Biosciences, −142.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 455th | Xenon Pharmaceuticals | −$345.9m | −4,612.1% |
| 456th | Immunitybio | −$351.4m | −310.2% |
| 457th | Arcus Biosciences | −$353.0m | −142.9% |
| 458th | Jazz Pharmaceuticals | −$356.1m | −8.3% |
| 459th | Bausch & Lomb | −$360.0m | −7.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Arcus Biosciences
- How much did Arcus Biosciences earn in fiscal 2025?
- Arcus Biosciences reported a net loss of $353.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $283.0m.
- What are the earnings per share of Arcus Biosciences?
- They were −$3.29 in fiscal 2025, compared with −$3.14 in fiscal 2024.
- What was the most profitable year for Arcus Biosciences?
- Of its last 9 fiscal years, fiscal 2021, with $53.0m.
- Where does Arcus Biosciences rank in its sector by net income?
- It ranks 457th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Arcus Biosciences come from?
- From the annual report (Form 10-K) that Arcus Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arcus Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Arcus Biosciences: the Arcus Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.